Physician profile
Jeane E Kiene
NPI 1053787234
$2,836.84
in general payments reported to CMS, 2019-2025
27 companies · $673 in 2025
The $673 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $188 · 2023: $837 · 2024: $678 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $525.02 | 2021-2025 | Cardiomems, Mitraclip |
| Novo Nordisk INC | $381.06 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $235.54 | 2022-2025 | Lifevest |
| Amgen INC. | $214.11 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $200.50 | 2022-2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $169.93 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $148.13 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $145.49 | 2022-2023 | Verquvo |
| Abiomed | $142.82 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $135.31 | 2021-2025 | |
| Tactile Systems Technology INC | $67.75 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $63.44 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Scpharmaceuticals INC. | $48.64 | 2023-2025 | |
| Csl Behring | $47.95 | 2023 | Kcentra |
| Medtronic, INC. | $35.97 | 2022-2025 | Micra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35.32 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.84 | 2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $28.92 | 2025 | Onpattro |
| Pfizer INC. | $28.23 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $24.66 | 2023 | Arcalyst |
| Biosense Webster, INC. | $24.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.64 | 2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $20.34 | 2024 | |
| Kestra Medical Technology Services, INC. | $17.42 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $16.45 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $13.74 | 2025 | Nexletol |
| Amarin Pharma, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeane Kiene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.